Get started
Author

Helle Jane Jacobsen

Observed names: Helle J Jacobsen, Helle J. Jacobsen, Helle Jacobsen
Observed institutions: Lund University, University of Cambridge, Aarhus University Hospital, Rigshospitalet, University of Oxford, Symphogen (Denmark), Stanford University
OpenAlex ID: A5114045543
A functional and structural basis for TCR cross-reactivity in multiple sclerosis
2002 · Heather L.E. Lang, Helle Jacobsen, et al. · Nature Immunology · 598
Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
2010 · Mikkel Wandahl Pedersen, Helle Jane Jacobsen, et al. · Cancer Research · 221
Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice
1998 · Ellen Christina Andersson, Bjarke Endel Hansen, et al. · Proceedings of the National Academy of Sciences · 152
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
2011 · Klaus Koefoed, Lucilla Steinaa, et al. · mAbs · 92
PDF
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
2015 · Helle J. Jacobsen, Thomas T. Poulsen, et al. · Clinical Cancer Research · 89
Myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice
2004 · Cathleen Rich, Jason M. Link, et al. · European Journal of Immunology · 61
PDF
Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
2015 · Mikkel W. Pedersen, Helle J. Jacobsen, et al. · Molecular Cancer Therapeutics · 56
Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors
2017 · Thomas Tuxen Poulsen, Michael Monrad Grandal, et al. · Clinical Cancer Research · 49
Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
2011 · Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, et al. · Clinical Cancer Research · 40
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
2017 · Michael M. Grandal, Serhiy Havrylov, et al. · Molecular Cancer Therapeutics · 28
Selection of a Novel and Highly Specific Tumor Necrosis Factor α (TNFα) Antagonist
2010 · Povilas Byla, Mikkel H. Andersen, et al. · Journal of Biological Chemistry · 19
PDF
In vivoimaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography
2015 · Carsten H. Nielsen, Mette M. Jensen, et al. · Oncotarget · 16
PDF
Non-depleting Anti-CD4 Antibody not only Prevents Onset but Resolves Sialadenitis in NOD Mice
2004 · Clare Thompson, Helle Jacobsen, et al. · Autoimmunity · 9
Abstract 4562: Superior targeting of the human epidermal growth factor receptor 2 (HER-2) with recombinant monoclonal antibody mixtures
2011 · Mikkel W. Pedersen, Helle J. Jacobsen, et al. · Cancer Research · 4
Supplementary methods from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
2023 · Michael M. Grandal, Serhiy Havrylov, et al.
Data from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
2023 · Michael M. Grandal, Serhiy Havrylov, et al.
Supplementary Figures 1-7 from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
2023 · Michael M. Grandal, Serhiy Havrylov, et al.
Supplementary Materials and Methods from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
2023 · Mikkel W. Pedersen, Helle J. Jacobsen, et al.
Supplementary Tables and Figures from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
2023 · Mikkel W. Pedersen, Helle J. Jacobsen, et al.
Data from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
2023 · Mikkel W. Pedersen, Helle J. Jacobsen, et al.
Data from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
2023 · Michael M. Grandal, Serhiy Havrylov, et al.
Data from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
2023 · Mikkel W. Pedersen, Helle J. Jacobsen, et al.
Supplementary Methods from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
2023 · Helle J. Jacobsen, Thomas T. Poulsen, et al.
Supplementary Figures and Tables from Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
2023 · Thomas Tuxen Poulsen, Michael Monrad Grandal, et al.
Supplementary information from Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
2023 · Thomas Tuxen Poulsen, Michael Monrad Grandal, et al.
Works count: 54
Citation count: 1,434
H-index: 12
I10-index: 12
Year
Topic
Type